Anavex Life Sciences Corp. (AVXL)
$3.13
$-0.11
(-3.40%)
As on 27-Aug-2026 16:18EDT
Market cap
$300 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-5.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.4
-
Face value
--
-
Shares outstanding
92,696,842
10 Years Aggregate
CFO
$-159.94 Mln
EBITDA
$-272.65 Mln
Net Profit
$-255.08 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
| -12.1 | 30.4 | 15.5 | -67.2 | -27.0 | -29.9 | 0.3 |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
| -66.9 | 15.2 | 0.5 | -46.6 | 221.1 | 108.5 | 66.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
3.1 | 300.3 | 0.0 | -34.1 | -- | -31.5 | -- | 2.5 |
| 88.6 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 249.4 | 16,614.0 | 1,054.4 | 755.9 | 5.7 | -- | 19.4 | 10.1 | |
| 77.9 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 55.3 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 106.9 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 543.7 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 611.6 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 367.9 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 149.5 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Anavex Life Sciences (AVXL)
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett... syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York. Read more
-
President, CEO, Secretary & Director
Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
-
President, CEO, Secretary & Director
Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
-
Headquarters
New York, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Anavex Life Sciences (AVXL)
What is the current share price of Anavex Life Sciences Corp (AVXL) Today?
The share price of Anavex Life Sciences Corp (AVXL) is $3.13 (NASDAQ) as of 27-Aug-2026 16:18 EDT. Anavex Life Sciences Corp (AVXL) has given a return of -26.98% in the last 3 years.
What is the current PB & PE ratio of Anavex Life Sciences Corp (AVXL)?
Since, TTM earnings of Anavex Life Sciences Corp (AVXL) is negative, P/E ratio is not available.
The P/B ratio of Anavex Life Sciences Corp (AVXL) is 2.46 times as on 21-Aug-2026, a 54 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-16.48 |
8.06 |
2024 |
-11.10 |
3.97 |
2023 |
-11.00 |
3.68 |
2022 |
-16.54 |
5.57 |
2021 |
-35.99 |
9.05 |
What is the 52 Week High and Low of Anavex Life Sciences Corp (AVXL)?
The 52-week high and low of Anavex Life Sciences Corp (AVXL) are Rs 10.40 and Rs 2.26 as of 28-Aug-2026.
What is the market cap of Anavex Life Sciences Corp (AVXL)?
Anavex Life Sciences Corp (AVXL) has a market capitalisation of $ 300 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Anavex Life Sciences Corp (AVXL)?
Before investing in Anavex Life Sciences Corp (AVXL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.